You are here: Home » Companies » News
Business Standard

Zydus Cadila gets USFDA approval for anti-depression drug

Drug will be manufactured at the group's formulations manufacturing facility at Moraiya in Ahmedabad

Press Trust of India  |  New Delhi 

Cadila's Moraiya plant near Ahmedabad
Cadila’s Moraiya plant near Ahmedabad

Drug firm on Thursday said it has received the final approval from the to market desvenlafaxine extended-release tablets, used to treat depression.

The approval from the (US FDA) is to market desvenlafaxine extended release in the strengths of 50 mg and 100 mg, said in a filing.

The drug will be manufactured at the group's formulations manufacturing facility at in Ahmedabad, it added.

The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.

Shares of Cadila Healthcare, the company's listed entity, were on Thursday trading 1.41 per cent higher at Rs 498.30 per scrip in the afternoon trade on

First Published: Thu, October 12 2017. 14:26 IST
RECOMMENDED FOR YOU